The relationship between inflammatory bowel diseases and kidney diseases

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Inflammatory bowel diseases occupy a significant place among all diseases of the gastrointestinal tract. According to D. Corica, the prevalence of extra-intestinal manifestations in inflammatory bowel diseases ranges from 6 % to 46 %. Gastroenterologists are well aware of local intestinal manifestations of these diseases. The etiology of extra-intestinal manifestations is still unclear. However, it is well known that these injuries are not limited to the intestines and one of the target organs is the kidneys. The following review presents the analysis of possible pathogenetic mechanisms of intestinal and kidney lesions, such as Crohn’s disease, ulcerative colitis and urolithiasis, tubulointerstitial nephritis, glomerulonephritis and amyloidosis of the kidneys.

全文:

受限制的访问

作者简介

Olga Barysheva

Petrozavodsk State University; V.A. Baranov Republican Hospital

编辑信件的主要联系方式.
Email: hosptherapy@mail.ru
ORCID iD: 0000-0002-2133-4849
SPIN 代码: 4896-5434

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Petrozavodsk; Petrozavodsk

Ruslan Simanov

Petrozavodsk State University; V.A. Baranov Republican Hospital

Email: ruslansimanov@yandex.ru
ORCID iD: 0000-0003-1246-7233
SPIN 代码: 3747-8245
俄罗斯联邦, Petrozavodsk; Petrozavodsk

参考

  1. Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016;10(2):226–235. doi: 10.1093/ecco-jcc/jjv138
  2. Bel’mer SV, Gasilina TV. Systems of the organs of digestion and organs of the elimination of urine: the morpho-functional and clinical generality [Internet]. Lechashhij vrach. 2013:6–20. Available from: https://www.lvrach.ru/2013/06/15435723. Accessed: Mar 12, 2022. (In Russ.)
  3. Monteiro RC, Berthelo L. Role of gut-kidney axis in renal diseases and IgA nephropathy. Curr Opin Gastroenterol. 2021;37(6):565–571. doi: 10.1097/MOG.0000000000000789
  4. Chen YY, Chen DQ, Chen L, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5. doi: 10.1186/s12967-018-1756-4
  5. Helvaci MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. Eurasian J Med. 2009;41(3):158–161.
  6. Prives MG, Lysenkov NK, Bushkovich VI. Human anatomy: textbook. Saint Petersburg; 2009. P. 266–267. (In Russ.)
  7. Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol. 2002;17(10):863–866. doi: 10.1007/s00467-002-0943-x
  8. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9(10):2300–2307. doi: 10.3748/wjg.v9.i10.2300
  9. Ambruzs JM, Walker PD, Larsen CP. The hystopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265–270. doi: 10.2215/CJN.04660513
  10. Pouria S, Barratt J. Secondary IgA nephropathy. Semin Nephrol. 2008;28(1):27–37. doi: 10.1016/j.semnephrol.2007.10.004
  11. Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–1196. doi: 10.1038/ng.3118
  12. Warling O, Bovy C, Coimbra C, et al. Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World J Gastroenterol. 2014;20(16):4811–4816. doi: 10.3748/wjg.v20.i16.4811
  13. Wilcox GM, Aretz HT, Roy MA, Roche JK. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology. 1990;98(3):786–791.
  14. Herrlinger KR, Noftz MK, Fellermann K, et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001;15(3):363–369. doi: 10.1046/j.1365-2036.2001.00940.x
  15. Poulou AC, Goumas KE, Dandakis DC, et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol. 2006;12(5):739–746. doi: 10.3748/wjg.v12.i5.739
  16. Fraser JS, Muller AF, Smith DJ, et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001;15(8):1131–1137. doi: 10.1046/j.1365-2036.2001.01041.x
  17. Tokuyama H, Wakino S, Konishi K, et al. Acute interstitial nephritis associated with ulcerative colitis. Clin Exp Nephrol. 2010;14(5):483–486. doi: 10.1007/s10157-010-0294-z
  18. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–539. doi: 10.1136/gut.51.4.536
  19. Shilov EM, Batyushin MM. Clinical recommendations for the diagnosis and treatment of chronic tubulointerstitial nephritis 2015 [Internet]. Available from: http://nonr.ru/wp-content/uploads/2013/11/Клинические-рекомендации-по-диагностике-и-лечению-хронического-тубулоинтерстициального-нефрита1.pdf. Accessed: Mar 12, 2022. (In Russ.)
  20. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7(4):295–300. doi: 10.1097/00054725-200111000-00003
  21. Parks JH, Worcester EM, O’Connor RC, Coe FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003;63(1):255–265. doi: 10.1046/j.1523-1755.2003.00725.x
  22. McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002;89(9):835–841. doi: 10.1046/j.1464-410x.2002.02739.x
  23. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–4831. doi: 10.3748/wjg.v12.i30.4819
  24. Dorofeev AJe, Rudenko NN, Derkach IA, Chechula JuV. Bowel diseases and kidneys. Look around that lecture. Journal of Gastroenterology of Ukraine. 2915;3(57):101–105. Available from: https://cyberleninka.ru/article/n/zabolevaniya-kishechnika-i-pochki. Accessed: Mar 12, 2022. (In Russ.)
  25. Chou YH, Huang CN, Li WM, et al. Clinical study of ammonium acid urate urolithiasis. Kaohsiung J Med Sci. 2012;28(5):259–264. doi: 10.1016/j.kjms.2011.11.004
  26. Ishii G, Nakajima K, Tanaka N, et al. Clinical evaluation of urolithiasis in Crohn’s disease. Int J Urol. 2009;16(5):477–480. doi: 10.1111/j.1442-2042.2009.02285.x
  27. Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol. 2014;27(3):241–245. doi: 10.1007/s40620-013-0034-z

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Barysheva O., Simanov R., 2022

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


##common.cookie##